Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00591643 · ClinicalTrials.gov registry record · Phase 1
Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)
A Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 1
- Development phase
- 93
- Enrollment target
NCT00591643: Completed Phase 1 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00591643 is a Phase 1 study that has completed, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 93 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00591643, a Phase 1 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 93 participants
- Enrollment target
Study Summary
The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic tool for imaging adrenal glands for many years with success in our hands. This is a diagnostic procedure. CT, MRI and Ultrasound can determine the size and presence or absence of tumor but cannot assess the function of the adrenal glands. To determine hormone concentrations from blood samples would involve more invasive catherization.
Interventions
- PROCEDURE Imaging, Adrenal acans
- RADIATION (NP-59)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 93 participants |
| Start Date | 1977-07 |
| Est. Completion | 2011-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00591643
The ClinicalTrials.gov registry entry for NCT00591643 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 93 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Imaging, Adrenal acans is the first listed.
NCT00591643 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00591643 about?
NCT00591643 is a clinical study titled "Adrenal Scans With Radioiodine-Labeled Norcholesterol (NP-59)". The purpose of this study is to find out if your adrenal glands are normal or abnormal. This can be determined by whether or not your adrenal gland concentrates more of a labeled building block of adrenal hormone, norcholesterol. This labeled material had been used as an investigative diagnostic too...
What is the current status of trial NCT00591643?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 93 participants. The study started on 1977-07. Estimated completion is 2011-03.
What interventions are being tested in trial NCT00591643?
The interventions under investigation include: Imaging, Adrenal acans (PROCEDURE), (NP-59) (RADIATION).
Who is sponsoring clinical trial NCT00591643?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.